In a galaxy far, far away, innovation is the key to success for pharmaceutical companies to overcome challenges, present and future. The force has been strong with recent breakthroughs in drug and vaccine development, such as mRNA vaccines and protein therapeutics. However, with the rise of carriers like colloidal systems, Lipid Nano Particles, and liposomes, new challenges have emerged, particularly in the areas of encapsulation and targeting.
These carriers not only protect the drugs, but they also allow for better targeting and assimilation, increasing their bio-availability and efficacy. But beware, young padawans, for these structures have a weakness – they are inherently unstable systems that can lead to phase separation and particle size growth. These destabilizations can have a negative impact on efficiency and bio-availability, inducing incorrect dosages and loss of specific surfaces.
Particle size analysis is a useful technique for measuring particle size variation, but it requires a significant amount of dilution and doesn’t provide any information on sedimentation and adhesion forces between particles, making it difficult to study destabilization reversibility.
However, fear not, for the Turbiscan technology provides a new hope with its non-dilution and native measurement of particle size and migration, offering an alternative characterization technique for measuring shelf-life. When coupled with a dispersing unit, the Turbiscan can even measure the recovery rate or the ability of a suspension to recover its initial properties after a shaking or mixing process, ensuring that it remains stable before injection or use.
Join us on this journey through the galaxy, where we will introduce you to the Turbiscan technology (SMLS – Static Multiple Light Scattering) and show you different case studies of its usage in the pharmaceutical industry. May the force be with you!
